As China’s biotech sector accelerates from fast follower to global innovator, U.S. venture investors are rethinking their strategies—and DealForma data highlights the shift, showing Chinese biotech licensing deals with global pharma surged to $68.7 billion in 2025, underscoring China’s growing influence on the industry’s competitive landscape. Read it here
